G. Sliutz et al., IMMUNOHISTOCHEMICAL AND SEROLOGICAL EVALUATION OF CD44 SPLICE VARIANTS IN HUMAN OVARIAN-CANCER, British Journal of Cancer, 72(6), 1995, pp. 1494-1497
The surface glycoprotein CD44 is widely distributed in different tissu
es. In contrast to healthy tissue, tumour samples show a more complex
pattern of CD44 expression, indicating a loss of splice control. Besid
e cell-surface expression, the measurement of soluble CD44 in serum of
cancer patients could be useful in early diagnosis and assessment of
disease status. We evaluated the surface expression of CD44 isoforms i
n 22 ovarian cancer patients by means of immunohistochemistry. Additio
nally, we investigated 134 serological samples of these patients for t
he occurrence of CD44 isoform expression. For CD44standard, CD44v5 and
CF44v6 mean serum levels in patients with clinically detectable or no
n-detectable ovarian cancer were 422.4+/-143.8 ng ml(-1) and 547.4+/-1
48.2 ng ml(-1) 12.3+/-7.9 ng ml(-1) and 21.9+/-12.2 ng ml(-1) and 105.
5+/-37.9 ng ml(-1) and 144.9+/-50.9 ng ml(-1) respectively (P-values n
ot significant). CD44 surface proteins containing epitopes encoded by
splice variants CD44v5, CD44v6 and CD44v7-8 were immunohistochemically
detected in 9% (n=2), 13% (n=3) and 4% (n=1) of the 22 tumour samples
respectively. In the present study we showed that in ovarian cancer C
D44 isoforms CD44v5 and CD44v6 are expressed in very low amounts by th
e tumours. In accordance with this, we found that the presence of tumo
ur is not associated with higher serum levels of CD44standard, CD44v5
and CD44v6 in preoperative serum samples in ovarian cancer patients.